Healthcare -
Biotechnology - NASDAQ - US
$ 7.38
-7.52 %
$ 29.3 M
Market Cap
-2.58
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
MiNK Therapeutics, Inc.
| Net Income | -10.8 M |
| Depreciation & Amortization | 215 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 1.81 M |
| Change in Working Capital | 460 K |
| Others | 386 K |
| Free Cash Flow | -9.56 M |
Cash Flow
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (10.8) | (22.5) | (28.0) | (30.2) | (16.2) | (23.8) |
| Depreciation & Amortization | 0.2 | 0.2 | 0.1 | 78 K | 55.1 K | 36.8 K |
| Deferred Income Tax | 0 | 0 | 0 | (0.4) | 0 | 0 |
| Stock Based Compensation | 1.8 | 3.9 | 3.0 | 1.7 | 87.8 K | 0.2 |
| Other Operating Activities | (1.3) | (0.3) | (2.8) | 12.2 | 8.1 | 4.5 |
| Change in Working Capital | 0.5 | 2.9 | 8.8 | 3.7 | (0.3) | 4.1 |
| Cash From Operations | (9.6) | (15.8) | (18.9) | (12.8) | (8.3) | (14.9) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 0 | 73.6 K | (0.3) | (0.2) | 95.2 K | (0.4) |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 0 | 73.6 K | (0.3) | (0.2) | 95.2 K | (0.4) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | (0.5) | (0.2) | 0 | 0 | 0 |
| Total Debt Repaid | 5.0 | 0 | 0 | 9.5 | 11.1 | 11.4 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 20 K | 70.5 K | 1.6 K | 150 | 0 | 0 |
| Cash From Financing Activities | 10.8 | (0.4) | (0.2) | 49.3 | 11.1 | 11.4 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 1.2 | (16.3) | (19.3) | 36.2 | 2.4 | (4.1) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (9.6) | (15.8) | (19.1) | (13.1) | (8.4) | (15.4) |